Allogene Therapeutics (ALLO) Other Accumulated Expenses (2018 - 2025)

Allogene Therapeutics (ALLO) has 8 years of Other Accumulated Expenses data on file, last reported at $2.4 million in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses rose 123.6% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (up 123.6% YoY), and the FY2025 full-year result was $2.4 million, up 123.6% from the prior year.
• Other Accumulated Expenses climbed to $2.4 million in Q4 2025, from $1.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.4 million in Q4 2025 to a low of $1.1 million in Q4 2024.
• A 5-year average of $1.8 million and a median of $1.8 million in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses tumbled 63.58% in 2021 and surged 123.6% in 2025, its largest moves.
• Tracing ALLO's Other Accumulated Expenses over 5 years: stood at $1.7 million in 2021, then rose by 21.38% to $2.1 million in 2022, then slipped by 14.59% to $1.8 million in 2023, then sank by 40.74% to $1.1 million in 2024, then surged by 123.6% to $2.4 million in 2025.
• Business Quant data shows ALLO's Other Accumulated Expenses at $2.4 million in Q4 2025, $1.1 million in Q4 2024, and $1.8 million in Q4 2023.